All studies with antibodies were performed to last one year and a half, or a little bit shorter. There are not many patients who got the treatment after one year and a half. Maybe the time is not the best framework because clinically you also use how much reduction in amyloid load in the brain with PET was done. Of course, PET is quite expensive. So, to follow up with PET, maybe in clinical reality you will use some proxy, for example phospho-tau from the blood...
All studies with antibodies were performed to last one year and a half, or a little bit shorter. There are not many patients who got the treatment after one year and a half. Maybe the time is not the best framework because clinically you also use how much reduction in amyloid load in the brain with PET was done. Of course, PET is quite expensive. So, to follow up with PET, maybe in clinical reality you will use some proxy, for example phospho-tau from the blood. But the question is also how you stop the treatment, when is time to stop? The criteria to stop the treatment should be a little bit better explained. Today we don’t have it approved in Europe. Only my colleagues from the US discussed how they stop. So usually in clinical trial setting or in university setting or very good memory clinics, you look not so much on the time, but what is the amyloid load in the brain? But I said you cannot stop the treatment over one night after one year and a half. It will be difficult to explain to patients that it is because there is no study. So, I think also that we have a potential when we start to treat patients, to combine this with registry-based study so we can see what happened after one year and a half for our patients. So, this should not be really to the day one year and a half. We should be more flexible, maybe some other clinical criteria. But of course, studies were done. So according to the evidence, we have evidence to one year and a half. But what’s next? It’s difficult when you find the patient to fulfil that criteria, how you stop the treatment and what happened. So, our role can be that we can contribute to the science to be able to give the registry-based studies.
